

Data Sheet


WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 $\begin{tabular}{lll} \textbf{Product Name} & : Pemigatinib \\ \textbf{Cat.No.} & : URK-V620 \\ \textbf{CAS No.} & : 1513857-77-6 \\ \textbf{Molecular Formula} & : C_{24}H_{27}F_2N_5O_4 \\ \end{tabular}$

Molecular Weight :487.5

Target : Solubility :



Biological Activity

Pemigatinib (INCB054828, INCB 054828) is a potent, selective, orally bioavailable inhibitor of FGFR1/2/3, potently inhibits the kinase activity of recombinant FGFR1, FGFR2 and FGFR3 enzymes and is highly selective against a panel of kinases including VEGFR2; inhibits the autophosphorylation of FGFR proteins with low nanomolar IC50 values and blocks signal transduction by FGFR to downstream markers of pathway activation. Cancer cell lines that have genetic alterations in FGFR1, FGFR2 and FGFR3 were uniquely displays sensitivity to cancer cell growth that have genetic alterations in FGFR1, FGFR2 and FGFR3 with IC50 in the range of 3-50 nM, with little to no effect on cancer cell lines or normal cells without FGFR dependence (IC50>1.5 uM); inhibits the growth of tumors that are dependent upon FGFR1, FGFR2 and FGFR3 activity in vivo, which is dose-dependent and correlated with pharmacodynamic inhibition of FGFR.

References

- 1. Phillip CC Liu, et al. Abstract 771: Preclinical characterization of the selective FGFR inhibitor INCB054828. AACR DOI: 10.1158/1538-7445.AM2015-771 Published August 2015.
- $2. \ Mansoor \ Saleh, \ et \ al. \ Abstract \ CT111: \ Preliminary \ results \ from \ a \ phase \ 1/2 \ study \ of \ INCB054828, \ a \ highly \ selective \ fibroblast \ growth \ factor \ receptor \ (FGFR) \ inhibitor, \ in \ patients \ with \ advanced \ malignancies.$

AACR DOI: 10.1158/1538-7445.AM2017-CT111 Published July 2017

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!